TNF and rheumatoid arthritis: Out of the subgroup of 43 RA patients treated with anti-TNF, 22 RA patients (11 RA IFNhigh and 11 RA IFNlow; infliximab n = 6, etanercept n = 10 and adalimumab n = 6) were evaluated at 6 months for treatment response using the DAS28 criteria.